Clinical Trial

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

Study acronym: REVEAL-ND NPM1
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain genetic mutations compared to chemotherapy alone. The study will also assess the safety of adding revumenib to chemotherapy.
Protocol Amendment History 4 changes
notable Trial sites expanded: 52 -> 83 locations 2026-07-24
notable Trial sites expanded: 24 -> 52 locations 2026-06-25
notable Trial sites expanded: 14 -> 24 locations 2026-05-21
notable Trial sites expanded: 9 -> 14 locations 2026-05-05
Trial Details
NCT Number NCT07211958
Lead Sponsor Syndax Pharmaceuticals
Conditions Acute Myeloid Leukemias
Enrollment 468 participants
Start Date 2025-11-25
Primary Completion 2029-06 (estimated)
Study Completion 2031-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-23